Prilium

Imidapril

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prilium

Property	Description
Active ingredient	Imidapril Hydrochloride
Form	Tablet (Oral)
Pharmacological class	Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose	Management of high blood pressure
Origin	Synthetic prodrug

Prilium is a well-established, synthetic prescription medication whose active substance is Imidapril Hydrochloride. It belongs to the major therapeutic class of cardiovascular agents known as Angiotensin-Converting Enzyme (ACE) Inhibitors, which are specifically utilized to regulate blood pressure and promote long-term cardiovascular stability.

What Type of Medicine is Imidapril and Its Classification?

The core classification of Prilium is as an ACE Inhibitor, a drug type that acts on the body’s Renin-Angiotensin-Aldosterone System (RAAS). Its active ingredient is a synthetic chemical entity. It is a targeted tool used as an established antihypertensive agent, frequently chosen for adults requiring management of elevated blood pressure. The active compound has a long duration of action within its class.

Composition, Form, and Prodrug Origin

Prilium is supplied as a single-component product in the tablet dosage form intended for oral administration. Imidapril is defined as a prodrug, meaning the substance itself is pharmacologically inactive upon ingestion. It must undergo metabolic conversion in the liver into its potent, active metabolite, Imidaprilat, to exert its therapeutic effects. This characteristic prodrug nature is a feature that differentiates its absorption and onset profile from immediately active ACE inhibitors.

What is the General Purpose of ACE Inhibition?

The general purpose of this medication is to reduce the excessive strain and workload placed on the heart and cardiovascular system by chronically elevated blood pressure. It achieves this benefit by promoting blood vessel widening throughout the body, which minimizes the resistance the heart must overcome to pump blood. This sustained effect helps maintain stability within the arterial system, supporting general cardiac health in scenarios such as managing persistent hypertension.

What side effects are possible with Prilium?

Possible Side Effects and Safety Information

Prilium (imidapril hydrochloride) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose official safety profile is based on regulatory standards that categorize adverse events by frequency and system involvement.

Category	Regulatory Documentation Overview
Adverse Reaction Scope	Adverse reactions are classified across major systems, including Respiratory (cough), Nervous System (headache, dizziness), Vascular (hypotension), and Gastrointestinal (nausea, diarrhea).
Frequency Classification	Common adverse reactions typically documented include a persistent, dry cough, headache, and dizziness. Less frequent effects are often classified as uncommon (e.g., vertigo, skin rash).
Serious Adverse Reactions	Regulatory documents highlight the risk of Angioedema, a potentially life-threatening swelling of the face, tongue, and throat that obstructs the airway. Other serious concerns include clinically significant Hyperkalemia (increased blood potassium levels) and Acute Renal Failure.
Population-Specific Safety	The medicine is contraindicated in the second and third trimesters of pregnancy due to documented risks of fetal injury. Caution is necessary for patients with pre-existing renal or hepatic impairment, who may require close monitoring.
Exposure-Related Patterns	Hypotension (low blood pressure) is explicitly noted as being more likely following the initiation of therapy or during periods of dose increase.
Safety Restrictions	The medicine is contraindicated in individuals with a history of angioedema related to previous ACE inhibitor use. Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with agents like Aliskiren is generally not recommended due to increased safety risks.

Regulatory Safety Summary: The official safety profile organizes adverse events to distinguish common effects from rare, potentially life-threatening reactions that require explicit warnings. This framework establishes the constraints and monitoring parameters against which the medicine's use is officially evaluated.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Prilium (Imidapril Hydrochloride), an ACE Inhibitor, primarily manifests through exaggerated pharmacological effects leading to severe cardiovascular compromise. Immediate medical advice must be sought if an overdose is suspected or following accidental ingestion, as regulator-mandated guidance requires immediate intervention.

Documented Manifestations and Severe Outcomes:

Overdosage may present with severe hypotension (extremely low blood pressure) and progression to shock (circulatory failure). Other officially documented signs include stupor (altered consciousness), bradycardia (slowed heart rate), and severe electrolyte disturbances. The most serious documented outcome is acute renal failure.

Required Emergency Actions and Monitoring:

Regulatory documents emphasize that the patient must be kept under close medical supervision, often requiring admission to an intensive care unit (ICU). Management is symptomatic and supportive. For acute hypotension, official procedures include placing the patient in the shock position and administering salt and volume supplementation. While no specific antidote is known, procedures such as gastric lavage and the use of adsorbents are considered for recent ingestion. Frequent monitoring of serum electrolytes and creatinine levels is explicitly required to assess renal status.

Therapeutic Uses of Prilium

Quick Facts on Prilium Use

Targeted Condition: Management of cardiac insufficiency.
Supported Uses: Addressing heart failure associated with mitral valve regurgitation.
Additional Use: May be utilized in the context of dilated cardiomyopathy.

Prilium (imidapril hydrochloride) is a medication authorized for use in veterinary medicine for dogs. Its function is to provide support in the management of cardiac insufficiency. The medication is indicated for the treatment of moderate to severe manifestations of heart failure that are associated with two specific cardiac conditions.

Specifically, it is used to manage heart failure caused by mitral regurgitation. This involves the backflow of blood through the mitral valve, which can lead to cardiac strain. Furthermore, the use of Prilium is relevant in the management regimen for heart failure that may be linked to dilated cardiomyopathy (DCM).

Imidapril hydrochloride is part of a therapeutic class that assists in achieving appropriate management of heart-related symptoms in the affected population.

Eligibility and Restrictions for Use

The official regulatory documentation for Prilium (imidapril hydrochloride) strictly defines the populations who may and may not use the product.

Eligible Population

The product is classified as a veterinary medicinal product and its use is strictly limited to dogs weighing more than a specified minimum (e.g., 2 kg or 8 kg, depending on the formulation). The eligible patient population is further constrained to dogs with a diagnosis of moderate to severe heart failure caused by mitral regurgitation or dilated cardiomyopathy.

Populations Who Must Not Use (Contraindications)

Prilium is contraindicated and must not be administered to dogs with the following conditions, as stated in the official label:

Low blood pressure.
Acute renal insufficiency.
Congenital heart disease.
Obstructive hypertrophic cardiomyopathy.
Hemodynamically relevant stenoses (such as aortic, mitral valve, or pulmonal stenosis).
Known hypersensitivity to an ACE inhibitor (the class of drug to which Prilium belongs).

Use Restrictions

Use is not recommended in pregnant or lactating bitches or in breeding dogs due to a lack of data. Additionally, treatment should be temporarily suspended in dogs with hypovolaemia or dehydration until their fluid and electrolyte balance has been restored.

What should I know about interactions with other medicines?

The official interaction profile for Prilium (imidapril hydrochloride) is structured around additive physiological effects and constraints established by regulatory authorities.

Interaction Scope

Property	Official Regulatory Documentation
Medicinal product categories with documented interactions	Angiotensin-II Receptor Blockers, Potassium-Sparing Diuretics, NSAIDs, Diuretics, Antidiabetic Agents, Tricyclic Antidepressants.
Specific interacting medicines (if explicitly listed)	Aliskiren, Sacubitril/Valsartan, Lithium, Allopurinol, Azathioprine, Procainamide, Gold (Aurothiomalate).
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction (additive effects on blood pressure or potassium levels); Reduced renal clearance of co-administered substance (e.g., Lithium).

Interaction Classifications

Property	Official Regulatory Documentation
Interaction severity classification	Contraindicated Combinations (e.g., Sacubitril/Valsartan, Aliskiren in high-risk patients); Clinically Significant Interactions.
Timing-based interaction rules	A mandatory 36-hour washout period is required when switching between Imidapril and Sacubitril/Valsartan (or vice versa).
Population-specific interaction notes	Contraindicated with Aliskiren specifically in patients with diabetes mellitus or renal impairment.

Official interaction statements:

Co-administration with Sacubitril/Valsartan is contraindicated and requires a 36-hour separation period due to the risk of angioedema.
Dual blockade of the RAAS with Aliskiren is strictly prohibited in patients with diabetes or pre-existing renal impairment.
Concomitant use with Potassium-Sparing Diuretics or Potassium Supplements is associated with an increased risk of Hyperkalaemia.
Imidapril reduces the renal clearance of Lithium, which officially results in an increased risk of Lithium toxicity (elevated plasma concentration).
Co-use of NSAIDs may lead to reduced renal function and can diminish the antihypertensive effect, a risk noted as being greater in the elderly population.
Alcohol may enhance the hypotensive effects of Imidapril.

Mechanism of Action

How Prilium Works: Mechanism of Action

Prilium acts as a selective competitive antagonist by binding directly to the Angiotensin II Type 1 Receptor ( AT1 R), which is the primary mediator of Angiotensin II ( AngII) effects. This molecular interaction physically blocks AngII from accessing and activating the receptor, thereby halting its associated cellular signaling cascade.

This blockade disrupts the effector arm of the Renin-Angiotensin-Aldosterone System ( RAAS), a key system regulating pressure and volume. Prevention of AngII-mediated signaling stops the stimuli that trigger vasoconstriction in vascular smooth muscle and reduce the release of Aldosterone from the adrenal cortex.

The resulting physiological modulation is two-fold: the lack of vasoconstrictive signals allows for vasodilation, causing a measurable decrease in Systemic Vascular Resistance (SVR). Concurrently, reduced Aldosterone activity leads to decreased renal reabsorption of sodium and water, which lowers the total circulating blood volume. These combined effects contribute to a decrease in the overall cardiac afterload and preload.

Dosage and Administration Information

How to Use Prilium: Official Administration Guidelines

Prilium (imidapril hydrochloride) is an oral medication formulated as a powder for oral solution for long-term administration to dogs for the management of chronic cardiac conditions. The usage of this medicine is standardized according to specific administration guidelines.

The official instructions establish a weight-based dosing schedule designed to deliver a precise amount of the active substance. The labeled dose is calculated at 0.25 mg of Imidapril per kg of the dog's body weight and must be administered once a day (daily). This medication can be administered without restriction concerning the animal's mealtime, meaning it may be given on an empty stomach or during a meal.

Prior to first use, the powder must be reconstituted by adding water to a designated mark on the vial to create the final oral solution. For proper administration, the solution must be shaken well before each use. The exact volume required for the dose must be measured precisely using the graduated syringe supplied with the product, which can then be given directly into the mouth or mixed with a small amount of food. To maintain its stability, the reconstituted solution requires storage in a refrigerator (2°C - 8°C). This protocol ensures consistent daily delivery necessary for continuous management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prilium

Evidence for Use in Essential Hypertension

The clinical evaluation for Prilium (Imidapril Hydrochloride) in populations with elevated blood pressure has relied on various research methods, primarily Randomized Controlled Trials (RCTs) performed by researchers. In these trials, researchers examined the medicine by comparing its use against an inactive substance (placebo) or against other well-established blood pressure medications.

In these research settings, the studies monitored the main outcome, which was the change in systolic and diastolic blood pressure. Studies reported measurements showing that the use of the medicine was observed in populations with measured changes in blood pressure and patterns related to achieving blood pressure goals. Evidence regarding long-term changes in events, such as stroke or heart attack, draws on the established evidence for the entire ACE inhibitor therapeutic class.

Evidence for Use in Chronic Heart Failure and Cardiac Support

Research has also explored the use of Prilium in populations with Chronic Heart Failure (CHF). The studies conducted for this indication were evaluated in patients with conditions often marked by functional limitations and physiological strain. The studies monitored outcomes reflecting daily functioning or activity level, such as exercise tolerance, and monitored key biomarkers. Specific clinical trials have also been conducted, and are relevant in regulatory context, for use in dogs diagnosed with heart failure associated with mitral valve regurgitation or dilated cardiomyopathy.

However, the evidence is limited regarding the medicine's specific data on very long-term outcomes in heart failure, such as survival rates or hospitalizations over many years. The findings describe patterns related to the established data for the ACE inhibitor therapeutic class in CHF, but certainty remains low for dedicated Imidapril-specific data on these major outcomes.

Study Landscape and Research Gaps

The evidence landscape for Prilium is characterized by a high volume of data supporting its association with changes in blood pressure, consistent with its therapeutic class. Data for certain groups remain insufficient. Furthermore, the reliance on ACE inhibitor class data for evidence related to major cardiovascular events is a documented feature of the research. These research limitations highlight what is known—and what is still uncertain—about this medicine.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Prilium (FAQ)

Q: How quickly should I expect Prilium to start working?

Prilium is a prodrug, meaning it must first be converted in the body to its active form, Imidaprilat. Official product information indicates that the active metabolite is quickly absorbed and typically reaches its highest concentration in the plasma around five hours after administration. This information provides a general indication of the time required for the active substance to be present.

Q: Is it normal to feel dizzy when first starting Prilium?

Dizziness and light-headedness are reported as common side effects of this medication. Official safety warnings note that hypotension (low blood pressure), which can lead to dizziness, is more likely to occur when therapy is first started. If this feeling persists or becomes severe, consultation with a healthcare provider is appropriate.

Q: Can Prilium affect sleep patterns?

According to some regulatory safety summaries, the medication has been reported to potentially cause sleepiness in some patients. Any significant changes to sleep habits or energy levels should be discussed with a healthcare professional.

Q: Are there any specific foods or drinks to avoid while taking Prilium?

Official information states that Prilium may be taken regardless of mealtime. Caution is advised regarding the consumption of alcohol, as it may enhance the blood pressure-lowering effects of the medicine. Due to the risk of increased potassium levels, concomitant use with potassium-sparing diuretics or potassium supplements is also advised against.

Q: How long does Prilium stay in your system after stopping it?

The active substance, Imidaprilat, has a long duration of action. Pharmacokinetic studies in the target species show that the active metabolite has a half-life of over 10 hours, which helps indicate how long the effects may persist after discontinuing the medicine.

Q: What should I do if I miss a dose of Prilium?

If a dose is missed, regulatory guidance states to take it as soon as you remember, unless it is almost time for your next scheduled dose. If it is nearly time for the next dose, the guidance is to skip the missed dose and return to your regular schedule. Do not take two doses at once to make up for a missed one.

Q: What is the scientific evidence supporting Prilium's use for its main condition?

The use of this medication is supported by clinical studies and data, including trials that compare its effects to a placebo (inactive substance) or other established treatments. The studies monitored key outcomes like changes in blood pressure and functional status to evaluate the medicine's activity and effects.

Q: What should I tell my dentist about taking Prilium?

You should inform your dentist that you are taking this medicine. Official documents note potential interactions with NSAIDs (a type of pain reliever often used in dentistry). Additionally, a rare but serious adverse effect called Angioedema (swelling of the face, tongue, and throat) is associated with this class of drug, which is relevant information for any dental procedure.

Q: Can Prilium be safely stopped suddenly?

Regulatory labels advise that the medication should not be stopped unless a healthcare provider instructs discontinuation. This is particularly important because official guidelines require a mandatory washout period when switching from certain other heart medications, indicating the need for careful management when discontinuing treatment.

Q: What are the most common side effects people report with Prilium?

According to official safety reports, the most commonly documented adverse reactions include a persistent dry cough, dizziness, light-headedness, headache, and a skin rash or itchiness. These are distinct from less common or serious effects.

Q: Does Prilium interact with common cold or flu medications?

Prilium has documented interactions with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which are frequently found in over-the-counter cold and flu remedies. Combining these may lead to a reduction in kidney function or a diminished antihypertensive effect. It is important to review the ingredients of cold medicines or consult with a healthcare professional before use.

Q: Can Prilium cause fatigue or low energy?

Official safety summaries mention that fatigue and a general feeling of weakness are noted as possible adverse reactions associated with this medication.

Q: Is Prilium safe for people with kidney problems?

The medicine is contraindicated (should not be used) in people with acute renal insufficiency (sudden, severe kidney failure). For those with impaired renal function (less severe kidney issues), a reduced dose may be necessary. Use in this population necessitates careful monitoring by a healthcare professional.

Q: Is Prilium a diuretic?

No, Prilium is classified as an ACE inhibitor, not a diuretic (water pill). However, by blocking the action of Angiotensin II, it reduces the release of Aldosterone, which then results in a decrease in the body's retention of salt and water. This effect helps to reduce overall blood volume.

Q: Why is Prilium sometimes prescribed for people who don't have high blood pressure?

While Prilium is commonly used as an antihypertensive (blood pressure lowering agent), regulatory documents also indicate its use for the management of certain cardiovascular conditions, such as Chronic Heart Failure.

Q: Can older adults take Prilium safely?

The medicine is sometimes used in older adults, but regulatory information specifies a distinct approach. Official documents indicate that the recommended initial dose for the elderly (age 65 or older) is typically lower than the standard adult starting dose.

Q: What happens if I drink alcohol while taking Prilium?

Official interaction statements warn that consuming alcohol while taking this medication may enhance its hypotensive effects (blood pressure lowering effects). This can increase the risk of symptoms like dizziness or light-headedness.

Q: Does Prilium affect blood sugar levels?

Prilium has documented interactions with Antidiabetic Agents (medications for diabetes). Official precautions note this due to a documented risk of altered blood glucose levels while taking the medicine.

How should Prilium be stored and disposed of?

Storage Conditions

Prilium (Imidapril Hydrochloride) storage requirements differ based on the product's state.

Product State	Temperature Requirement	Additional Rule
Powder (Before preparation)	Do not store above 25 C	Store out of the sight and reach of children
Solution (After preparation)	Store in refrigerator (2 C to 8 C)	Use child-proof stopper; discard after 77 days

Disposal Instructions

Any unused or expired medicine must be disposed of in accordance with national and local requirements. To protect the environment, Prilium must not be disposed of via wastewater, sinks, toilets, or household waste. Follow instructions from a medical professional regarding pharmaceutical waste return programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.